According to new research, men at the highest chance of developing prostate cancer may have their investigations expedited if their hereditary risk was taken into account.
The impact of adding genetic risk for cancer into the GP triage and referral processes was examined in a significant study conducted by the University of Exeter and published in the British Journal of Cancer.
The study came to the conclusion that taking genetic risk into account could enhance recommendations for individuals in need and, more crucially, prevent invasive biopsy examinations for those with minimal cancer risk. Men who are most at risk for prostate cancer may receive an earlier diagnosis if their hereditary risk is evaluated in primary care.
Prostate cancer accounts for around a quarter of new cancer cases in men approximately 52,000 men are diagnosed per year in the UK alone. It is the second most common cause of cancer death in men in the UK, and if it is detected early rather than late, the chance of survival for five years is doubled.
Although symptoms are widespread and sometimes misinterpreted, early detection could prevent 14% of deaths from prostate cancer. GPs make around 800,000 suspected prostate cancer referrals annually in the UK.
According to the research team, adding genetic risk for cancer to GP triage might expedite 160,000 men for rapid investigation while allowing 320,000 of them to avoid referral and uncomfortable investigation.
Lead author Dr. Harry Green, an independent Research Fellow at the University of Exeter Medical School, said: “Our study is the first to demonstrate that incorporating genetic risk into GP’s risk assessment of patients’ symptoms of possible prostate cancer could result in faster referral for those at most risk.”
Prostate cancer is one of the most common cancers in men, and you think of all the hours of NHS time and resources going into this testing. If this new way of assessing patients could cut down on the number of men who have to experience that, I think it would have huge benefits, both to patients and to the NHS.
Richard Westlake
At the moment, a prostate Specific Antigen (PSA) test is used to investigate men with erectile dysfunction or urination problems, but the accuracy of the test is unclear, and false positive results are common.
Only one in three men with a positive PSA test have cancer. An invasive and unpleasant biopsy is often needed for diagnosis. Research shows the PSA test can miss around 15 percent of cancers.
Using more than 250 known genetic variations associated with the disease, the team estimated the genetic risk for prostate cancer. These genetic variations are used to create a single “genetic risk score” that identifies a person’s hereditary propensity for prostate cancer. They applied this to data from 6,390 White European men from UK Biobank, whose records showed they had seen a GP with potential prostate cancer symptoms.
The study’s lead investigator, Dr. Sarah Bailey, Senior Research Fellow at the University of Exeter Medical School, said: “This is potentially an exciting new strategy for early cancer detection. Not only can high-risk patients be fast-tracked, but those at low risk can safely avoid invasive investigations. Using this technique would align well to the NHS Long Term Plan, which pledges to become the first national health care system to offer whole genome sequencing as part of routine care. This could be a clear example of improving early diagnosis, and therefore treatment and survival.”
Kirsten Higgins, whose family are long-term supporters of the University of Exeter, funded the study. She said: “We’re delighted to be able to support the Exeter team to explore the application of genomics data in a more targeted approach to prostate cancer detection. It’s very exciting to see the real-world benefit to patients of this innovative new approach.”
Months of anxiety and testing
Richard Westlake endured 18 months of anxiety before he was declared clear of prostate cancer. Now 74, Mr. Westlake, a retired Devon County Councillor and railway train driver, was first alerted in November 2015 that his night-time trips to the toilet may be a sign of the condition, combined with a raised PSA test.
Mr. Westlake, from Exeter, then faced months of hospital visits, first for a biopsy, then for a more invasive biopsy procedure, along with x-rays and a combination of other tests, each followed by an anguished wait for the result. Finally, after a second biopsy in June 2017, he was given the all-clear.
“I was quite surprised to be honest,” he said of the result. “I’d been expecting it to be positive, all that time. But I wasn’t celebrating I’d been through a very difficult time, with all that testing, waiting, unpleasantness, and anxiety. I knew it had to be done, and all the staff I met were brilliant, but it was a horrible, drawn-out experience.”
“Prostate cancer is one of the most common cancers in men, and you think of all the hours of NHS time and resources going into this testing. If this new way of assessing patients could cut down on the number of men who have to experience that, I think it would have huge benefits, both to patients and to the NHS.”
The study, which was published in the British Journal of Cancer, is titled “Applying a genetic risk score for prostate cancer to 2 males with lower urinary tract symptoms in primary 3 care to predict prostate cancer diagnosis: a cohort 4 study in the UK Biobank.”
